New IPF drug shows early promise in small safety trial
NCT ID NCT03422068
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called BI 1015550 (Nerandomilast) in 15 people with idiopathic pulmonary fibrosis (IPF). Participants took either the drug or a placebo twice daily for up to 12 weeks. The study aimed to see if the drug is safe and how the body processes it, laying groundwork for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1015550 (Nerandomilast, JASCAYD®)
What this could lead to
If this drug proves safe and effective in larger trials, it could become a new treatment option for idiopathic pulmonary fibrosis.
What could go wrong
This is a very early Phase 1 trial with only 15 participants, so safety and effectiveness are not yet established. The drug may not work in larger studies or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medisch Centrum
Rotterdam, 3015 CE, Netherlands
-
Fraunhofer ITEM
Hanover, 30625, Germany
-
HYKS Keuhkosairauksien tutkimusyksikkö
Helsinki, 00290, Finland
-
Hospital de Bellvitge
L'Hospitalet de Llobregat, 08907, Spain
-
Odense University Hospital
Odense, 5000 C, Denmark
-
Poli Univ A. Gemelli
Roma, 00168, Italy
-
Royal Brompton Hospital
London, SW3 6NP, United Kingdom
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
St. Antonius ziekenhuis, locatie Nieuwegein
Nieuwegein, 3435 CM, Netherlands
-
TYKS
Turku, 20520, Finland
-
Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany